Your browser doesn't support javascript.
loading
Characterisation of the NRF2 transcriptional network and its response to chemical insult in primary human hepatocytes: implications for prediction of drug-induced liver injury.
Copple, Ian M; den Hollander, Wouter; Callegaro, Giulia; Mutter, Fiona E; Maggs, James L; Schofield, Amy L; Rainbow, Lucille; Fang, Yongxiang; Sutherland, Jeffrey J; Ellis, Ewa C; Ingelman-Sundberg, Magnus; Fenwick, Stephen W; Goldring, Christopher E; van de Water, Bob; Stevens, James L; Park, B Kevin.
Afiliação
  • Copple IM; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, L69 3GE, UK. ian.copple@liverpool.ac.uk.
  • den Hollander W; Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institute, 171-77, Stockholm, Sweden. ian.copple@liverpool.ac.uk.
  • Callegaro G; Division of Toxicology, Leiden Academic Centre for Drug Research, Leiden University, 2333 CC, Leiden, The Netherlands.
  • Mutter FE; Division of Toxicology, Leiden Academic Centre for Drug Research, Leiden University, 2333 CC, Leiden, The Netherlands.
  • Maggs JL; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, L69 3GE, UK.
  • Schofield AL; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, L69 3GE, UK.
  • Rainbow L; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, L69 3GE, UK.
  • Fang Y; Centre for Genomic Research, Institute of Integrative Biology, University of Liverpool, Liverpool, L69 7ZB, UK.
  • Sutherland JJ; Centre for Genomic Research, Institute of Integrative Biology, University of Liverpool, Liverpool, L69 7ZB, UK.
  • Ellis EC; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA.
  • Ingelman-Sundberg M; Liver Cell Lab, Unit for Transplantation Surgery, Department of Clinical Science, Intervention and Technology (CLINTEC), Karolinska University Hospital Huddinge, 141-86, Stockholm, Sweden.
  • Fenwick SW; Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institute, 171-77, Stockholm, Sweden.
  • Goldring CE; Department of Hepatobiliary Surgery, Aintree University Hospital NHS Foundation Trust, Liverpool, L9 7AL, UK.
  • van de Water B; MRC Centre for Drug Safety Science, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, L69 3GE, UK.
  • Stevens JL; Division of Toxicology, Leiden Academic Centre for Drug Research, Leiden University, 2333 CC, Leiden, The Netherlands.
  • Park BK; Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, 46285, USA.
Arch Toxicol ; 93(2): 385-399, 2019 02.
Article em En | MEDLINE | ID: mdl-30426165
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hepatócitos / Fator 2 Relacionado a NF-E2 / Redes Reguladoras de Genes / Doença Hepática Induzida por Substâncias e Drogas Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Hepatócitos / Fator 2 Relacionado a NF-E2 / Redes Reguladoras de Genes / Doença Hepática Induzida por Substâncias e Drogas Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article